Evaluation of Concomitant Use of Anticancer Drugs and Herbal Products : From Interactions to Synergic Activity
CAM is used by about 40% of cancer patients in Western Countries, with peaks of 80% for breast cancer patients. Cancer patients use CAM to boost immune function, to control cancer symptoms and treatment-related side effects, and to improve health-related quality of life (HR-QoL) and survival. Unfortunately, self-prescription of natural remedies in cancer patients can lead to unexpected toxicities and can reduce the effectiveness of cancer therapy. Although CAM usually refers to all the "natural or organic" products/methods that are generally considered less toxic, there are concerns about drug interactions, especially in patients participating in clinical trials with experimental agents. Despite the claims of the promising and potential benefits made by prescribers, many CAMs lack clear scientific evidence of their safety and efficacy. Given the widespread use of CAM-both clearly declared and overt-in this review, we focused on the most important known data on the risk of interactions between biologics and oncology drugs with the goal of opening up CAM in accordance with the meaning of integrative medicine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancers - 14(2022), 21 vom: 23. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Berretta, Massimiliano [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alternative |
|---|
| Anmerkungen: |
Date Revised 06.01.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers14215203 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348722079 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348722079 | ||
| 003 | DE-627 | ||
| 005 | 20231226040927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers14215203 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348722079 | ||
| 035 | |a (NLM)36358622 | ||
| 035 | |a (PII)5203 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Berretta, Massimiliano |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of Concomitant Use of Anticancer Drugs and Herbal Products |b From Interactions to Synergic Activity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.01.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a CAM is used by about 40% of cancer patients in Western Countries, with peaks of 80% for breast cancer patients. Cancer patients use CAM to boost immune function, to control cancer symptoms and treatment-related side effects, and to improve health-related quality of life (HR-QoL) and survival. Unfortunately, self-prescription of natural remedies in cancer patients can lead to unexpected toxicities and can reduce the effectiveness of cancer therapy. Although CAM usually refers to all the "natural or organic" products/methods that are generally considered less toxic, there are concerns about drug interactions, especially in patients participating in clinical trials with experimental agents. Despite the claims of the promising and potential benefits made by prescribers, many CAMs lack clear scientific evidence of their safety and efficacy. Given the widespread use of CAM-both clearly declared and overt-in this review, we focused on the most important known data on the risk of interactions between biologics and oncology drugs with the goal of opening up CAM in accordance with the meaning of integrative medicine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a alternative | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a complementary | |
| 650 | 4 | |a interactions | |
| 650 | 4 | |a medicine | |
| 650 | 4 | |a synergism | |
| 700 | 1 | |a Dal Lago, Lissandra |e verfasserin |4 aut | |
| 700 | 1 | |a Tinazzi, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Ronchi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a La Rocca, Gaspare |e verfasserin |4 aut | |
| 700 | 1 | |a Montella, Liliana |e verfasserin |4 aut | |
| 700 | 1 | |a Di Francia, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Facchini, Bianca Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Bignucolo, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Montopoli, Monica |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 14(2022), 21 vom: 23. Okt. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:21 |g day:23 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers14215203 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 21 |b 23 |c 10 | ||